S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Critical asset just had biggest fall on record (Ad)
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Critical asset just had biggest fall on record (Ad)
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Critical asset just had biggest fall on record (Ad)
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Critical asset just had biggest fall on record (Ad)
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet

Orchard Therapeutics (ORTX) Stock Forecast & Price Target

Notice: This company has been marked as potentially delisted and may not be actively trading.

Orchard Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 3 Analyst Ratings

Analysts' Consensus Price Target

$21.67
29.74% Upside
High Forecast$34.00
Average Forecast$21.67
Low Forecast$15.00
TypeCurrent Forecast
3/4/23 to 3/3/24
1 Month Ago
2/2/23 to 2/2/24
3 Months Ago
12/4/22 to 12/4/23
1 Year Ago
3/4/22 to 3/4/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$21.67$21.67$21.67$45.00
Predicted Upside29.74% Upside130.59% Upside130.59% Upside692.04% Upside
Get Orchard Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ORTX and its competitors with MarketBeat's FREE daily newsletter.


ORTX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ORTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Orchard Therapeutics Stock vs. The Competition

TypeOrchard TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.33
2.68
2.48
Consensus RatingHoldModerate BuyHold
Predicted Upside29.74% Upside1,800.15% Upside6.76% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/6/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Stavropoulos
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral
10/5/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$16.00-0.19%
8/9/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$34.00+572.60%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 07:19 PM ET.












ORTX Price Target - Frequently Asked Questions

What is Orchard Therapeutics's consensus rating and price target?

According to the issued ratings of 3 analysts in the last year, the consensus rating for Orchard Therapeutics stock is Hold based on the current 2 hold ratings and 1 buy rating for ORTX. The average twelve-month price prediction for Orchard Therapeutics is $21.67 with a high price target of $34.00 and a low price target of $15.00. Learn more on ORTX's analyst rating history.

Do Wall Street analysts like Orchard Therapeutics more than its competitors?

Analysts like Orchard Therapeutics less than other Medical companies. The consensus rating for Orchard Therapeutics is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how ORTX compares to other companies.

Does Orchard Therapeutics's stock price have much upside?

According to analysts, Orchard Therapeutics's stock has a predicted upside of 130.59% based on their 12-month stock forecasts.


Stock Ratings Reports and Tools

This page (NASDAQ:ORTX) was last updated on 3/3/2024 by MarketBeat.com Staff